Table 2. Association of radiation dose and clinical factors with objective response (OR).
Sixty patients had follow-up PET/CT imaging available to determine response, with 46 patients achieving OR. Wilcoxon rank-sum tests and Fisher’s exact tests were performed, with median (IQR); n (%) presented.
| Characteristic | No objective response (n=14) | Objective response (n=46) | p-value |
|---|---|---|---|
| Dose to tumor (Gy) | 54.0 (45.2—61.5) | 167.0 (97.0—216.8) | <0.001 |
| Unknown | 2 | 4 | |
| Dose to normal parenchyma (Gy) | 31.5 (27.5—52.8) | 85.0 (46.2—107.8) | 0.002 |
| Unknown | 2 | 4 | |
| Number of extrahepatic metastatic sites | 2.5 (2.0—3.0) | 1.5 (1.0—2.8) | 0.014 |
| TARE device | <0.001 | ||
| Glass microspheres | 3 (7.5,) | 37 (92%) | |
| Resin microspheres | 11 (. 5%) | 9 (45%) | |
| Extent of disease | 0.3 | ||
| Unilobar | 2 (12%) | 14 (88%) | |
| Bilobar | 12 (27%) | 32 (73%) | |
| Number of systemic therapy lines | 8.0 (6.2—12.5) | 8.5 (5.0, 12.0) | 0.5 |
| Hormone receptor status | |||
| Estrogen receptor | 0.5 | ||
| ER-negative | 2 (13%) | 13 (87%) | |
| ER-positive | 12 (27%) | 33 (73%) | |
| Progesterone receptor | >0.9 | ||
| PR-negative | 6 (24%) | 19 (76%) | |
| PR-positive | 8 (23%) | 27 (77%) | |
| HER2 receptor | 0.4 | ||
| HER2-negative | 13 (26%) | 37 (74%) | |
| HER2-positive | 1 (10%) | 9 (90%) | |
| Pre-TARE laboratory values | |||
| Total bilirubin (mg/dL) | 0.6 (0.4—1.0) | 0.5 (0.3—0.9) | 0.2 |
| AST (units/L) | 57.5 (28.0—73.8) | 30.5 (21.5—72.0) | 0.2 |
| ALT (units/L) | 39.0 (23.2—54.0) | 33.5 (18.0—53.8) | 0.5 |
| Platelets (x10^9/L) | 197.0 (156.5—287.8) | 202.5 (156.0—268.5) | 0.9 |
| Percent of normal parenchyma treated | 45 (28—64) | 50 (34—69) | 0.6 |
| Unknown | 2 | 4 | |
| Anticoagulation | 0.7 | ||
| Not anticoagulated | 11 (25%) | 33 (75%) | |
| Anticoagulated | 3 (19%) | 13 (81%) |